Prosthetic joint infections (PJI) are severe complications arising after joint replacement surgeries, affecting approximately 1–3% of patients. PJIs are a major cause of revision arthroplasties, increasing the demand for advanced and targeted therapeutics. The growing burden of orthopedic procedures and rising antibiotic resistance is accelerating research in antibacterial, bacteriophage, and biofilm-disrupting therapies.

PJI Pipeline Analysis: Drug Development Landscape

The Prosthetic Joint Infections Pipeline Analysis Report by Expert Market Research offers a detailed view of therapeutics under clinical development. It includes over 100 pipeline drugs across 50+ companies, evaluating efficacy, safety, drug class, clinical phase, and route of administration.

Pipeline Segmentation by Phase

Phase II: 32%, reflecting strong mid-stage development

Phase IV: Post-marketing studies supporting long-term safety

Phase III: 21%, showing progress toward late-stage validation

Phase I: 15.79%, highlighting early-stage clinical interest

Pipeline Segmentation by Drug Class

Small molecules – novel antibiotics targeting resistant strains

Peptides – anti-biofilm and antimicrobial agents

Monoclonal antibodies – immunotherapeutic approaches

Gene therapies – precision treatment for persistent infections

Polymer-based drug conjugates – targeted delivery systems

Route of Administration

Oral – systemic antibiotic and small molecule therapies

Parenteral – injectable biologics, peptides, and conjugates

Others – experimental delivery methods in early-phase trials

Key Pipeline Highlights

PHAXIAM GLORIA Study: Phase II trial evaluating anti-Staphylococcus aureus bacteriophage therapy combined with antibiotics for PJIs

TNP-2092 (TenNor Therapeutics): Multi-target antibacterial agent administered intra-articularly, inhibiting bacterial RNA polymerase, DNA gyrase, and topoisomerase IV, targeting biofilm-associated infections

Biofilm-disrupting strategies: Emerging as a critical approach to enhance antibiotic efficacy and reduce infection recurrence

Epidemiology of Prosthetic Joint Infections

Incidence: 1–3% of joint replacement surgeries

Economic burden: Treatment costs up to EUR 21,937 per case

Mortality: Five-year rate up to 21.12%

PJIs remain a major clinical challenge, highlighting the need for innovative and targeted therapeutics

Get a Free Sample Report with Table of Contents.

Key Players in PJI Clinical Trials

Trellis Bioscience LLC, Armata Pharmaceuticals, Phaxiam Therapeutics

Osteal Therapeutics, TenNor Therapeutics Limited, Precisio Biotix Therapeutics, Nabi Biopharmaceuticals

Arrevus Inc., BioMed Valley Discoveries, Cubist Pharmaceuticals LLC

These companies are advancing therapies including antibiotics, bacteriophages, and biofilm-targeted drugs, aiming to improve outcomes, reduce recurrence, and enhance post-surgical recovery.

Conclusion

The prosthetic joint infections pipeline demonstrates strong innovation across small molecules, peptides, and biologics, with mid- and late-stage trials showing promising efficacy. Novel bacteriophage therapies and biofilm-disrupting agents are set to transform PJI management, addressing antibiotic resistance challenges and unmet clinical needs worldwide.